Company Analysis

Purple Biotech Ltd. (PPBT)

Nasdaq: PPBT · Pharmaceutical Preparations · Rehovot, IL · filing with the SEC since 2014
Grade4.7
◀ Past 6.1● Present 3.9▶ Future 4.4
3 est.
The companyfiscal 2020, as filed
Revenue$1.0M0.0%
Net income$28.1M+376.4%
Earnings per sharen/a
Operating cash flow$1.7M+186.6%
Cash$11.2M+156.5%
Debtn/a
Shareholders’ equity$79.8M+634.4%
Shares, diluted11.5M-40.6%
Return on equity-274.3%
The recordfrom its filings
Filings in 202635
Newest filingNov 12 · SCHEDULE 13G
Annual reportMar 19, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted6
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PPBT · research, not advice